About the company - Ziccum
Ziccum develops new formulations of biological drugs. With the company's patented technology LaminarPace, dry formulations of products that are currently available in liquid form are developed. This allows Ziccum to open up new markets, create new patents and generate revenue from the sale of licenses to the new form of preparation.

Through its patented technology LaminarPace, Ziccum is the only company in the world to offer gentle drying of biological drugs at room temperature. This opens up the opportunity to develop and patent new formulations of biological drugs and offer better stability, longer durability and simpler storage and transportation requirements. This gives a competitive advantage, cost savings and the opportunity to address more and bigger markets. New forms of preparation and the process of producing these can also be protected by new patents so that the competitive advantage lasts over time. LaminarPace has been validated through internal, published studies and external projects where Ziccum has carried out feasibility studies on behalf of the client.

Ziccum, located in Lund, was founded as a spinout from Inhalation Sciences, which was successfully listed on Spotlight (formerly Aktietorget) in September 2017. Ziccum follow the same path and will be listed on Spotlight in October 25th, 2018.

For additional information about Ziccum please visit the company website: http://ziccum.com/ and http://ziccum.com/investors/presentations/

Ziccums vision is to provide safe and effective medicines in all environments and situations worldwide and to minimize expensive and impractical fridge and freezer transport and storage.


Application Specialist

Develop and to grow Ziccum to a world leader in providing safe and effective biological drugs in the area of dry formulation

With Ziccums patented technology LaminarPace our objective is to develop new formulations of biologics. By developing dry formulations of products presently present only in liquid form, Ziccum can open up new markets and create new patents. Dry form is always sought in the development of new drugs. The benefits of dry form (tablets, powders, etc.) are many. It increases the stability of the product and thus its life span, it facilitates the entire transport chain from factory to patient, enabling the distribution of drugs to new locations where, for example, refrigerator and freezer storage is a major challenge. This means that patients who treat themselves, in their homes, can access safer and more efficient drugs.

For traditional drugs, or small molecules, dry formulation stands for more than 95% of all products on the world market. The corresponding figure for biological drugs, such as vaccines, antibodies, peptides and proteins are only 20%. This is largely due to the sensitivity of the biological preparations to extreme temperatures, which in turn excludes the use of traditional drying methods based on either high or low temperatures.
Ziccum has a unique and patented technology that is well documented, with clear customer benefits. The company focus on a market (biologics) where the history, trends and needs clearly indicates the value of being able to produce products in dry form but where the technical solutions for doing this has been lacking. The next step is to adapt the technology for commercial production and present our offer to potential partners in the pharmaceutical industry.
Ziccum has the technology and offer that has the potential to make a big difference for large populations who need access to vaccines and drugs, and for large pharmaceutical companies that want to streamline the logistics of their products and thereby increase market potential.

If you decide to work for Ziccum it means you will:
• work in a company that will have a paramount impact on possibilities to a paradigm shift concerning the ability to formulate dray formulations of biological drugs
• be a part of a company that will enable patients worldwide access to safer and more efficient drugs
• work in a company with short decision paths and with a high level of personal responsibility
• close and frequent interactions with the CEO and the board
• as the company is small, you must have a “can do” attitude and be comfortable in situations where you must be more “hands-on”
• work in a company with a clear objective - to develop and to grow Ziccum to a world leader
in providing safe and effective biological drugs in the area of dry formulation
• as the company grows, there are excellent and planned opportunities for your development

The position
Ziccum is looking for an Application Specialist to work in the laboratory with product development and formulation (dry formulate biological drugs), process and method development, product characterization, troubleshooting and compatibility. You will compile lab data and present the results to the CEO. You have a documented experience working with various lab techniques – HPLC, spectrophotometry etc. and possible also in the upscaling phase. You need to be experienced in the protein-based chemistry area.
You will work in a key role with Ziccums development projects essential to the future of the company and the growth of the company. Ziccums technology will probably (not decided yet) be out-licensed to external partners laboratories primarily in Europe but also in the US and then you will be on site to set up the technology, training, etc. The position involves close cooperation with the CEO and project manager. You will be located at Ziccum’s in Lund and report to the CEO. After some months, when the company have signed partners, you have to calculate approximately 2 days of traveling in average per week.

The product – the patented technology LaminarPace
LaminarPace is a patented technology that gently dries chemicals, vaccines, biologics and drug substances at room temperature, keeping their active ingredient intact. The technology has successfully dried over 100 different types of biologics and chemicals, including peptides and antibodies. Current conventional drying technologies either freeze or bake substances. Operating at -80 °C or +80 °C means there is little chance of delicate, temperature-sensitive materials, like proteins and peptides, remaining active after being dried. By micronizing substances at room temperature, LaminarPace produces robust, active dry powder versions of delicate biologics, peptides, proteins and antibodies. 80% of biologic therapies are currently formulated as liquid solutions, making them costly and difficult to handle and transport.
The market for biological drugs is large and in strong growth. In 2017, biological drugs accounted for one third of total drug sales globally, equivalent to $ 208 billion. By 2024, this figure is estimated to have increased to $ 380 billion or 38% of global pharmaceutical sales. [EvaluatePharma® World Preview 2018, Outlook to 2024, 11th Edition - June 2018]

Contact information
For inquires and more information about the position, please contact Jarl Molin, senior recruitment consultants at PeakSearch. Mail: jarl.molin@peaksearch.se phone: +46 70 560 20 56